1Svendsen PF et al, Incretin hormone secretion in women with polycystic ovary syndrome., roles of obesity, insulin sensitivity, and treatment with metformin[J]. Metabolism Clinical and ex- perimental, 2009,58 : 586.
2Tan Susanne et al. Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) vari- ants in patients with polycystic ovary syndrome (PCOS) BMC [J]. Medical Genetics, 2010,11-12.
4Fruzzetti Fet al. Effect of long-term naltrexone treatment on en- docrine, profile, clinical features, and insulin sensitivity in obese wotnen with potycystic ovary syndrome[J]. Fertil Steril, 2002,77 (5) :936.
5Tucci S et al. Evidence for association of polycystic ovary syn- drome in caucasian women with a marker at the insulin receptor gene locus[J]. J Clin Endocrinol Metab, 2001,1 :446.
6Villuendas Get al. Association between the D19S884 marker at the insulin receptor geng locus and polycystic ovary syndrome [J]. Fertil Steril, 2003,1 : 219.
7Siegel Set al. A C/T single nucleotide polymorphism at the tyro- sine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome[J]. Fertil Steril, 2002,78 (6) : 1240.
7Skal ba P. Progress in gynecological endocrinology [ J]. Ginekol Pol, 2008,79(12) :877-881.
8Moran LJ, Misso ML, Wild RA, et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome:a systematic review and meta analysis [ J ]. HumReprod Update,2010, 16(4) :347-363.
9Krrolyi Z. The pathomeehanism of polycystic ovary syndrome in the light of recent research findings. Orv Hetil,2012,153 : 1567-1569.
10Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril,2004,81:19-25.
